ReviewApplied microbiology and biotechnology2024
Motility of Acinetobacter baumannii: regulatory systems and controlling strategies.
Review in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Should I stay or should I go? DNA damage thresholds drive stay-or-go decisions inJournal of bacteriology · 2026Review
- The transcription factor LafI integrates control of flagellar motility and T3SS1-mediated virulence inApplied and environmental microbiology · 2026Article
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Effect of polymyxin resistance evolution on the fitness costs of Acinetobacter baumannii and the underlying mechanisms of polymyxin resistance.Scientific reports · 2026Article
- Synergistic Inhibition ofMicroorganisms · 2026Article
- New Insights intoPathogens (Basel, Switzerland) · 2026Review
- Virulence arsenal of Acinetobacter baumannii: mechanisms driving persistence and resistance.Archives of microbiology · 2026Review
- Therapeutic strategies against biofilm-associated multidrug-resistantFrontiers in microbiology · 2026Review
- A novel GntR-ABC efflux system mediates oxidative stress response, drug resistance, motility and virulence inFrontiers in microbiology · 2026Article
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
- Genomic insights into ST85 and ST158 belonging to recently emerged global clones of multidrug-resistant Acinetobacter baumannii isolates from Egypt: in vitro assessment of repurposed drug-antibiotic combinations.Annals of clinical microbiology and antimicrobials · 2025Article
- Targeting PilA in Acinetobacter baumannii: A Computational Approach for Anti-Virulent Compound Discovery.Molecular biotechnology · 2025Article
- Genomic and phenotypic characterization of six multidrug-resistant Acinetobacter pittii isolates.Scientific reports · 2025Article
- When the Last Line Fails: Characterization of Colistin-ResistantPathogens (Basel, Switzerland) · 2025Article
- Rosaceae Honey: Antimicrobial Activity and Prebiotic Properties.Antibiotics (Basel, Switzerland) · 2025Article
- Killing two birds with one stone: emergence of colistin and cefiderocol resistance in a mucoid MDRFrontiers in microbiology · 2025Article
- A chionodracine-derived peptide, KHS-Cnd, as an anti-virulence agent against multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Drug susceptibility of uropathogens isolated from patients treated at the Mazovian Specialized Hospital in Radom.Acta biochimica Polonica · 2025Article
- Biofilm and surface-motility profiles under polymyxin B stress in multidrug-resistant KAPE pathogens isolated from Ghanaian hospital ICUs.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acinetobacter baumannii is a Gram-negative opportunistic zoonotic pathogenic bacterium that causes nosocomial infections ranging from minor to life-threatening. The clinical importance of this zoonotic pathogen is rapidly increasing due to the development of multiple resistance mechanisms and the synthesis of numerous virulence factors. Although no flagellum-mediated motility exists, it may move through twitching or surface-associated motility. Twitching motility is a coordinated multicellular movement caused by the extension, attachment, and retraction of type IV pili, which are involved in surface adherence and biofilm formation. Surface-associated motility is a kind of movement that does not need appendages and is most likely driven by the release of extra polymeric molecules. This kind of motility is linked to the production of 1,3-diaminopropane, lipooligosaccharide formation, natural competence, and efflux pump proteins. Since A. baumannii's virulence qualities are directly tied to motility, it is possible that its motility may be used as a specialized preventative or therapeutic measure. The current review detailed the signaling mechanism and involvement of various proteins in controlling A. baumannii motility. As a result, we have thoroughly addressed the role of natural and synthetic compounds that impede A. baumannii motility, as well as the underlying action mechanisms. Understanding the regulatory mechanisms behind A. baumannii's motility features will aid in the development of therapeutic drugs to control its infection. KEY POINTS: • Acinetobacter baumannii exhibits multiple resistance mechanisms. • A. baumannii can move owing to twitching and surface-associated motility. • Natural and synthetic compounds can attenuate A. baumannii motility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.